

REMARKS

Claims 16, 17 and 19-39 were pending in the present application. Claims 16, 17, 19-25, 29 and 33-36 were rejected. Claims 26, 30 and 37 are herein amended. Claims 16-25 and 34-36 are herein cancelled without prejudice. No new matter has been added.

Applicants' Response to Claim Objections

On the Office Action Summary Sheet, the May 19, 2009 Office Action indicates that claims 26-28, 30-32 and 37-39 are objected to. However, the Office Action itself does not contain any discussion of these claims. As such, Applicants' representative contacted the Examiner by telephone to clarify whether these claims are regarded as reciting allowable subject matter, but are objected to as being dependent upon a rejected base claim. As indicated in the interview summary dated June 5, 2009, the Examiner confirmed that these claims recite allowable subject matter. Applicants herein re-write claims 26, 30 and 37 in independent form. Thus, allowance of these claims, and all claims dependent thereon, is respectfully requested.

Claims 17 and 19-21 were rejected under 35 U.S.C. §112, first paragraph, as failing to comply with the written description requirement.

The Office Action maintains the rejection with respect to the broader claims directed at the genus including variants of SEQ ID NO: 1. Applicants herein cancel these claims. Thus, this rejection is moot.

Claims 21, 25, 29 and 33 were rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The Office Action states that claims 21, 25, 29 and 33 are indefinite because "if a candidate compound that acts as an agonist of G protein-coupled receptor p2y9 functions as an inhibitor of carcinoma cell invasion, a candidate compound that acts as an antagonist of G protein-coupled receptor p2y9 would not function as an inhibitor of carcinoma cell invasion, and vice versa." In essence, the Office Action regards claims 21 and 29 as conflicting with claims 25 and 33.

In response, Applicants herein cancel claims 21, 25 and 29. Based on at least page 44, lines 3-4 and original claim 7, it is clear that activation of p2y9 decreases activity that causes carcinoma cell invasion. Therefore, the subject matter of claim 33 is retained, and the subject matter of claims 21, 25 and 29 is cancelled. Favorable reconsideration is respectfully requested.

Allowable Subject Matter

As noted above, the Examiner indicated that claims 26-28, 30-32 and 37-39 recite allowable subject matter. Since claim 29 is cancelled, claim 33 also recites allowable subject matter. Applicants herein re-write these claims in independent form. Therefore, allowance of claims 26-28, 30-33 and 37-39 is respectfully requested.

Application No.: 10/542,217
Art Unit: 1646


Supplemental Amendment
Attorney Docket No.: 082464

Should the Examiner deem that any further action by applicants would be desirable to place the application in condition for allowance, the Examiner is encouraged to telephone applicants' undersigned attorney.

If this paper is not timely filed, Applicants respectfully petition for an appropriate extension of time. The fees for such an extension or any other fees that may be due with respect to this paper may be charged to Deposit Account No. 50-2866.

Respectfully submitted,

WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP

A handwritten signature in black ink, appearing to read 'Ryan B. Chirnomas', is written over the printed name and title.

Ryan B. Chirnomas
Attorney for Applicants
Registration No. 56,527
Telephone: (202) 822-1100
Facsimile: (202) 822-1111

RBC/nrp